Abstract: Substituted cinnamic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them. Compounds of the formula I which may be obtained by reaction of a compound II with guanidine.

Abstract: Substituted cinnamic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them.

Abstract: Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or a diagnostic, and medicament comprising them Chromans of the formula I and of the formula 1a having the meanings R(A), R(B), R(C) and R(1) to R(8) indicated in the claims are outstandingly suitable for preparing a medicament for blocking the K+ channel which is opened by cyclic adenosine monophosphate (cAMP); and further for preparing a medicament for inhibiting gastric acid secretion; for the treatment of ulcers of the stomach and of the intestinal region, in particular of the duodenum, for the treatment of reflux esophagitis, for the treatment of diarrheal illnesses, for the treatment and prevention of all types of arrhythmias including ventricular and supraventricular arrhythmias, and for the control of reentry arrhythmias and for the prevention of sudden heart death as a result of ventricular fibrillation.

Abstract: This invention relates to a method of treating a chronic fibrogenetic liver disorder and/or an acute liver disorder and/or complications associated therewith, comprising administering to a patient a therapeutically effective amount of a bradykinin antagonist. Particular complications associated with said liver disorders include portal hypertension, decompensation phenomena such as ascites, edema formation, hepatorenal syndrome, hypertensive gastropathy and colopathy, splenomegaly and hemorrhagic complications in the gastrointestinal tract due to portal hypertension, collateral circulation and hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.

Abstract: The invention relates to the use of nonpeptide bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders (hepatic cirrhosis and hepatic fibrosis), acute liver disorders and for the prevention of complications, in particular for the prophylaxis or treatment of portal hypertension, decompensation symptoms such as ascites, edema formation, hepatorenal syndrome, hypertensive gastropathy and colopathy, splenomegaly and hemorrhagic complications in the gastrointestinal tract due to portal hypertension, collateral circulation and hyperemia and a cardiopathy as a result of a chronically hyperdynamic circulatory situation and its consequences.

Abstract: Hirudin derivatives can be prepared by the selective enzymic replacement of a part of the molecule with an amino derivative. The hirudin derivatives are suitable for preparing pharmaceuticals having an anticoagulatory effect.

Abstract: The invention relates to peptides of the formulaR.sup.N --L--N--B.sup.2 --R.sup.C (I)in which R.sup.N denotes an acyl radical, L denotes a radical of a lipophilic, neutral .alpha.-amino acid, N denotes a radical of an neutral .alpha.-amino acid, B.sup.2 denotes the radical of a basic .alpha.-amino acid, and R.sup.C denotes an amido radical; a process for their preparation, agents containing these peptides, and their use.

Abstract: Compounds I ##STR1## with R equal to hydrogen or (C.sub.1 -C.sub.4)-alkyl,X equal to (CH.sub.2).sub.n with n=1-4, unsubstituted or substituted, andAr is equal to an aromatic or heteroaromatic system, optionally substituted,and their pharmaceutically tolerated salts are valuable pharmaceuticals for the treatment of cerebral edema or diarrhea.

Abstract: A description is given of a process for the preparation of a compound of the formula I ##STR1## in which R.sup.1, R.sup.2 and R.sup.3 (identical or different) represent H, alkyl having 1-2 carbon atoms and F, Cl, Br or I;R.sup.4 represents H, alkyl having 1-4 carbon atoms, n represents the numbers 2-5, andR.sup.5 represents a radical which can be eliminated under physiological conditions or represents hydrogen, and its physiologically tolerated salts.They are effective remedies for diarrhea.

Abstract: Compounds of the formula I ##STR1## with R.sup.1 equal to H or (cyclo)alk(en)yl, R.sup.2 equal to H or alkyl, R.sup.3 equal to alkyl, R.sup.4 /R.sup.5 equal to H, alkyl or acyl, and Y equal to H, alkyl, CF.sub.3 or Hal, are described, as are processes for the preparation thereof.They are effective diuretics and antihypertensive agents with a lipid-lowering action.

Abstract: A description is given of the use of amino-substituted benzoic acid derivatives of the formula I ##STR1## in which R.sup.1 and R.sup.2 denote hydrogen, (cyclo)alkyl, unsubstituted or substituted phenyl or naphthyl, or R.sup.1 and R.sup.2 together denote a chain --(CH.sub.2).sub.m -- with m=3 to 6, or together denote a chain --(CH.dbd.CH).sub.n -- with n equal to 2 or 3; R.sup.3 denotes hydrogen, halogen or alkyl; R.sup.4 denotes hydrogen or NO.sub.2 ; R.sup.5 denotes hydrogen or a radical which can be eliminated under physiological conditions; for the preparation of a remedy for diarrhea.

Abstract: Compounds of the formula I ##STR1## with R.sup.1 equal to H or (cyclo)alk(en)yl, R.sup.2 equal to H or alkyl, R.sup.3 equal to alkyl, R.sup.4 /R.sup.5 equal to H, alkyl or acyl, and Y equal to H, alkyl, CF.sub.3 or Hal, are described, as are processes for the preparation thereof.They are effective diuretics and antihypertensive agents with a lipid-lowering action.

Abstract: The invention relates to 2-aminomethylphenols of the formula I ##STR1## in which R.sup.1 and R.sup.2 represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or benzyl which is optionally substituted by alkyl, alkoxy or halogen, R.sup.3 and R.sup.5 denote hydrogen, halogen, alkyl or alkoxy, R.sup.4 denotes halogen, alkyl or cycloalkyl and R.sup.6 and R.sup.7 represent hydrogen or alkyl, it being possible for the radicals R.sup.1 and R.sup.2, R.sup.6 R.sup.7 and/or two of the radicals R.sup.3, R.sup.4 and R.sup.5 to form an alkylene chain which is optionally substituted by methyl groups and which, in the case of the radicals R.sup.1, R.sup.2, R.sup.6 and R.sup.7, can also be interrupted by oxygen atoms, sulfur atoms and/or imino groups, and to physiologically acceptable salts thereof, a process for their preparation, and their use and to pharmaceutical formulations based on these compounds.

Abstract: The invention relates to 2-aminomethylphenols of the formula I ##STR1## in which R.sup.1 and R.sup.2 represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or benzyl which is optionally substituted by alkyl, alkoxy or halogen, R.sup.3 and R.sup.5 denote hydrogen, halogen, alkyl or alkoxy, R.sup.4 denotes halogen, alkyl or cycloalkyl and R.sup.6 and R.sup.7 represents hydrogen or alkyl, it being possible for the radicals R.sup.1 and R.sup.2, R.sup.6 and R.sup.7 and/or two of the radicals R.sup.3, R.sup.4 and R.sup.5 to form an alkylene chain which is optionally substituted by methyl groups and which, in the case of the radicals R.sup.1, R.sup.2, R.sup.6 and R.sup.7, can also be interrupted by oxygen atoms, sulfur atoms and/or imino groups, and to physiologically acceptable salts thereof, a process for their preparation, and their use and to pharmaceutical formulations based on these compounds.

Abstract: 5-(4-Chloro-3-sulfamoylbenzoyl)-2,3-dihydro-2-benzofurancarboxylic acids of the formula I ##STR1## in which R.sup.1 and R.sup.2 are identical or different and represent hydrogen, halogen or methyl, both as racemic mixtures and in the form of their optical isomers, and their physiologically tolerated salts are described, as is their preparation. They are outstanding diuretics and saluretics with an additional uricosuric component.

Abstract: What are disclosed are salidiuretic compounds of the formula ##STR1## and physiologically acceptable salts thereof, wherein R is phenyl, furyl or thienyl, intermediates of said compounds, methods for making said compounds, salidiuretic pharmaceutical preparations containing said compounds or salts, and methods for treating humans and other mammals with such compounds or salts.

Abstract: The invention relates to base-substituted anthranilic acids of the formula I ##STR1## in which R denotes furyl, thienyl or phenyl, and to physiologically acceptable salts thereof, and also to a process for their preparation, to an agent containing these and to their use as medicaments.

Abstract: Benzenesulfonamide derivatives as defined in the specification have an outstanding salidiuretic action. Some of the compounds exhibit a significant increase in the excretion of uric acid and the uric acid clearance. They are distinguished by a long-lasting period of action and are suitable for the treatment of hypertonic conditions in humans, optionally in combination with anti-hypertonic agents.